COMP <GO>
NUS vs UNH // REVENUE GROWTH (YOY)
Nu Skin Enterprises Inc. (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: NUS 4
— UNH 6
▲ REVENUE GROWTH (YOY) LEADER: UNH
LAST: $4.78 (+2.80%) • MKT CAP: $232.7M
revenue-growth
-14.30%
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
revenue-growth
3.33%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NUS VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NUS | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.40% | 88.31% | -18.91 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.70% | 12.38% | -5.68 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 20.15% | 6.25% | +13.90 | NUS | /fcf-yield <GO> |
| Operating Margin | 4.40% | 5.32% | -0.92 | UNH | /operating-margins <GO> |
| Net Profit Margin | 10.80% | 3.53% | +7.27 | NUS | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -14.30% | 3.33% | -17.63 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 5.18% | 2.29% | +2.89 | NUS | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.54 | 3.09 | +0.45 | NUS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.9 | 55.1 | -5.20 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $232.7M | $359.43B | -$359.20B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NUS REV | UNH REV | NUS GROSS % | UNH GROSS % | NUS FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.49B | $447.57B | 69.4% | 88.7% | $46.0M | $16.07B |
| FY 2024 | $1.73B | $400.28B | 68.2% | 88.3% | $70.2M | $20.70B |
| FY 2023 | $1.97B | $371.62B | — | 89.6% | $118.6M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NUS // BETA —
UNH // BETA 0.33